Randomised controlled trial confirms benefit of enhanced recovery after surgery on length of stay in ovarian cancer: How low can we go?

We applaud the authors of the PROFAST Trial [1], as this is the first published randomised controlled trial of Enhanced Recovery After Surgery (ERAS) versus conventional management (CM) focussed exclusively on advanced ovarian cancer surgery. The main finding of the study was a reduction in median length of stay (LOS) from 9 days in the CM group to 7 days in the ERAS group. There was a small reduction in readmissions favouring ERAS; however, no reduction in complications was reported.